Siemens Healthineers stock slumps 13% but analysts stay bullish on recovery
Siemens Healthineers has faced a tough start to the year, with its share price dropping nearly 13% and hitting a 52-week low of €38.70. Despite the downturn, major financial institutions remain confident in the company's long-term prospects.
The medical technology firm has struggled in a difficult market climate. Recent geopolitical tensions, particularly in the Middle East, have added pressure to the European medtech sector. Yet analysts suggest a stabilisation in these tensions could help the industry recover.
JPMorgan has kept an 'overweight' rating on Siemens Healthineers, setting a price target of €61.30. The bank highlights the company's operational quality, arguing its strengths in imaging and laboratory diagnostics are undervalued. Stabilising margins in these areas could bring JPMorgan's projected upside back into focus.
Barclays analysts have also dismissed the recent share decline. They reaffirmed their positive outlook, pointing to the company's fundamental resilience rather than short-term market fluctuations.
While Siemens Healthineers' stock has fallen this year, key analysts continue to back its operational performance. A potential easing of geopolitical risks and stronger margins in core divisions may support a rebound in the coming months.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
- Inspired & Paddy Power Extend Virtual Sports Partnership for UK & Ireland Retail
- South West & South East England: Check & Object to Lorry Operator Licensing Now
